EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Endogenous Levels, Detection Time, and Symptoms of Gamma‐Hydroxybutyric Acid: Results From a Placebo‐Controlled Clinical Trial

Kathrine Bohn Faldborg iD, Lambert Kristiansen Sørensen iD, Jørgen Bo Hasselstrøm iD, Charlotte Uggerhøj Andersen iD

Basic & Clinical Pharmacology & Toxicology · 2025-12 · 137 (6)

DOI: 10.1111/bcpt.70133 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Basic & Clinical Pharmacology & Toxicology, online erschienen am 08.11.2025. Verfasst von Kathrine Bohn Faldborg und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Forensic Medicine, Aarhus University, Aarhus, Denmark. Hauptthemen laut MEDLINE: Sodium Oxybate, Hydroxybutyrates, Substance Abuse Detection. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: The Council of the Danish Victims Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gamma‐hydroxybutyric acid (GHB), a potential agent in drug‐facilitated sexual assault, is difficult to detect due to rapid elimination, endogenous presence, and possible postsampling formation. We conducted a randomised, placebo‐controlled trial in 30 healthy volunteers, administering 50‐mg/kg sodium oxybate or placebo, to investigate symptoms, pharmacokinetics and endogenous concentrations. Blood was collected in fluoride‐oxalate (FX) tubes, and urine and oral fluid in additive‐free tubes, at baseline, 1, 2, 3, 4, 6, 12, and 24 (urine only) hours post‐administration. Samples were immediately cooled, stored at −70°C, and analysed using LC–MS/MS. Maximal endogenous GHB concentrations were 0.050 μg/mL in blood, 0.41 μg/mL in urine, and 0.93 μg/mL in oral fluid. GHB‐treated participants reported vertigo and fatigue, with no significant memory impairment. Median peak GHB concentrations post‐administration were 50, 440, and 29 μg/mL in blood, urine, and oral fluid, respectively. Oral fluid appeared unsuitable for GHB detection. As endogenous concentrations in blood did not exceed 0.050 μg/mL, a theoretical cut‐off with a safety margin (0.25 μg/mL) would yield a negligible risk of false positives in samples collected in FX tubes and cooled immediately. Applying this cut‐off extended the blood detection window ≥ 2 h in all GHB‐treated participants, surpassing that in urine at a 6‐μg/mL cut‐off.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium OxybateHydroxybutyratesSubstance Abuse DetectionHumansMaleAdultFemaleYoung AdultSalivaHealthy VolunteersTandem Mass SpectrometryDouble-Blind MethodChromatography, LiquidTime FactorsMiddle Aged

Stichwörter der Autor:innen

GHBdetection windowdrug‐facilitated sexual assaultforensic toxicologygamma‐hydroxybutyrate

Substanzen

Sodium OxybateHydroxybutyrates4-hydroxybutyric acid

Autor:innen und Institutionen

  • Department of Forensic Medicine, Aarhus University, Aarhus, Denmark.
  • Department of Clinical Pharmacology, Aarhus University Hospital, Aarhus, Denmark.

ORCID-Profile: Kathrine Bohn Faldborg, Lambert Kristiansen Sørensen, Jørgen Bo Hasselstrøm, Charlotte Uggerhøj Andersen

Förderung

  • The Council of the Danish Victims Fund

Zitieren

APA

Faldborg, K. B., Sørensen, L. K., Hasselstrøm, J. B., & Andersen, C. U. (2025). Endogenous Levels, Detection Time, and Symptoms of Gamma‐Hydroxybutyric Acid: Results From a Placebo‐Controlled Clinical Trial. Basic & Clinical Pharmacology & Toxicology, 137(6). https://doi.org/10.1111/bcpt.70133

Vancouver

Faldborg KB, Sørensen LK, Hasselstrøm JB, Andersen CU. Endogenous Levels, Detection Time, and Symptoms of Gamma‐Hydroxybutyric Acid: Results From a Placebo‐Controlled Clinical Trial. Basic & Clinical Pharmacology & Toxicology. 2025;137(6). doi:10.1111/bcpt.70133

BibTeX
@article{Faldborg2025,
  author = {Faldborg, Kathrine Bohn and Sørensen, Lambert Kristiansen and Hasselstrøm, Jørgen Bo and Andersen, Charlotte Uggerhøj},
  title = {Endogenous Levels, Detection Time, and Symptoms of Gamma‐Hydroxybutyric Acid: Results From a Placebo‐Controlled Clinical Trial},
  journal = {Basic & Clinical Pharmacology & Toxicology},
  year = {2025},
  volume = {137},
  number = {6},
  doi = {10.1111/bcpt.70133}
}
Kostenlos starten →